Histamine 2 antagonists in allergic rhinitis. Relationship of clinical response and serum concentrations of total and specific IgE antibody levels

Arch Otolaryngol Head Neck Surg. 1989 Aug;115(8):950-3. doi: 10.1001/archotol.1989.01860320060019.

Abstract

During a double-blind clinical trial of a histamine (H2) antagonist (ranitidine) in monitoring allergic rhinitis, the clinical response, total serum IgE levels, and Parietaria IgE antibody levels were measured. Ranitidine induces an improvement in scores of subjective and objective symptoms, a decrease in total serum IgE levels, and no significant variations in Parietaria IgE antibody levels. Since H2 antagonists seem to induce these improvements by acting on suppressor T cells bearing H2 receptor, as shown in our previous studies, it is hypothesized that the lymphocytic subset that regulates the total IgE synthesis is not the same as that governing specific IgE synthesis.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Airway Obstruction / drug therapy
  • Edema / drug therapy
  • Female
  • Humans
  • Immunoglobulin E / analysis*
  • Immunoglobulin E / classification
  • Male
  • Nose Diseases / drug therapy
  • Pollen / immunology
  • Radioallergosorbent Test
  • Ranitidine / pharmacology*
  • Ranitidine / therapeutic use
  • Rhinitis, Allergic, Seasonal / blood*
  • Rhinitis, Allergic, Seasonal / drug therapy

Substances

  • Immunoglobulin E
  • Ranitidine